Inactive Instrument

Highlights Akers Biosciences Inc Nasdaq

Equities

US00973E1029

Highlights

Unlock all the news: Be the first to know and act before the market!

MyMD Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data	09/04	MT
Top Premarket Gainers	09/04	MT
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02/04	CI
MyMD Pharmaceuticals Regains Compliance With Nasdaq's Minimum Bid Listing Requirement	05/03	MT
MyMD Pharmaceuticals, Inc. Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis	06/12	CI
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11	CI
Mymd Pharmaceuticals, Inc. Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD, Reduced Acute Inflammatory Pain	19/23/19	CI
MyMD Pharmaceuticals, Inc. to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-a Market Disrupter, at BioFuture 2023	04/23/04	CI
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI
FDA Accepts MyMD Pharmaceuticals, Inc. Investigational New Drug Application for Phase 2 Study of Oral Tnf-A Inhibitor Mymd-1®? in Rheumatoid Arthritis	14/23/14	CI
Mymd Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral Tnf-A Inhibitor Mymd-1® in Sarcopenia/Age-Related Frailty	31/23/31	CI
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16	CI
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	01/23/01	CI
Mymd Pharmaceuticals, Inc. to Present Data from Preclinical Study of its MYMD-1 Product Candidate in A Rheumatoid Arthritis (Ra) Model at the 2023 Society of Toxicology Annual Meeting	20/23/20	CI
MyMD Pharmaceuticals' Supera-CBD Determined by US Drug Enforcement Administration as Not Controlled Substance	02/23/02	MT
MyMD Pharmaceuticals, Inc. Announces U.S. Drug Enforcement Administration Determines Supera-CBD Is Not A Controlled Substance or Listed Chemical	02/23/02	CI
MyMD Pharmaceuticals, Inc. Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-Inhibitor MYMD-1 at the Society of Toxicology 2023 Annual Meeting	01/23/01	CI
MyMD Pharmaceuticals, Inc. to Present Data on Oral TNF-a Inhibitor MYMD-1 at the British Society for Immunology Congress 2022	06/22/06	CI
MyMD Pharmaceuticals, Inc. Announces Publication of Phase 1 Data for Oral Tnf-Alpha Inhibitor Mymd-1® in Peer-Reviewed Journal Drug Research	14/22/14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Akers Biosciences Inc Nasdaq

Equities

US00973E1029

Highlights

Filters